menu
    • menu
    [{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"TaiRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Foslinanib","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bora Pharmaceuticals \/ TaiRx","highestDevelopmentStatusID":"8","companyTruncated":"Bora Pharmaceuticals \/ TaiRx"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"CT-G20","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bora Pharmaceuticals \/ Celltrion","highestDevelopmentStatusID":"6","companyTruncated":"Bora Pharmaceuticals \/ Celltrion"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"DotBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"DB007","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bora Pharmaceuticals \/ DotBio","highestDevelopmentStatusID":"4","companyTruncated":"Bora Pharmaceuticals \/ DotBio"}]

    Find Clinical Drug Pipeline Developments & Deals by Bora Pharmaceuticals

    Menu

    Bora Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    Key Services KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bora Pharmaceuticals

                            Taiwan
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothBora Pharmaceuticals- Making success more certain.

                            Lead Product(s) : DB007

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : DotBio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bora Biologics, DotBio Enter Strategic CMC Development Collaboration

                            Details : The collaboration aims to advance the development of DotBio’s Tri-Specific Antibody DB007 for the treatment of Cancer.

                            Product Name : DB007

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            January 09, 2025

                            Lead Product(s) : DB007

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : DotBio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Bora Pharmaceutical

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bora Pharmaceuticals

                            Taiwan
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothBora Pharmaceuticals- Making success more certain.

                            Lead Product(s) : CT-G20

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Celltrion

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bora and Celltrion Join Forces To Distribute Oral Drugs Across APAC

                            Details : Under the partnership, Bora will manufacture and commercialize a range of oral dosage form drugs (OSD), including CT-G20, a hypertrophic cardiomyopathy treatment candidate, across the APAC region.

                            Product Name : CT-G20

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 04, 2023

                            Lead Product(s) : CT-G20

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Celltrion

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            Bora Pharmaceutical

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bora Pharmaceuticals

                            Taiwan
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothBora Pharmaceuticals- Making success more certain.

                            Lead Product(s) : Foslinanib,Sorafenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : TaiRx

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bora Pharmaceuticals Partners with TaiRx

                            Details : CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific fact...

                            Product Name : CVM-1118

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 27, 2022

                            Lead Product(s) : Foslinanib,Sorafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : TaiRx

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            Bora Pharmaceutical

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth